Background {#Sec1}
==========

Cerebrospinal fluid (CSF) biomarkers are being used to improve the clinical diagnostic accuracy of Alzheimer's disease (AD) \[[@CR1], [@CR2]\]. Established markers include levels of amyloid-beta of 42 amino acids (Aβ~1--42~), total tau protein (t-tau), and phosphorylated tau protein (p-tau) \[[@CR3]\]. The most studied isoform of p-tau is that with phosphorylation at threonine 181 (p-tau~181~), while there are other phosphorylated tau epitopes that have not been thoroughly investigated for their clinical utility such as serine 199 and threonine 231 \[[@CR4]\]. Although studies on large neuropathology case series suggest that tau pathology precedes amyloid-β plaque pathology \[[@CR5]\], the opposite holds true for the detectable biomarker counterparts in CSF \[[@CR6]\]. Thus, there is a discrepancy between neuropathology and detectable clinical biomarker findings \[[@CR7]\]. Furthermore, since the current biomarkers are already changed in the mild cognitive impairment (MCI) stage and remain stable during the clinical course, they cannot be used as prognostic markers. As single markers they are not completely specific for AD given that there is a slight overlap with other neurodegenerative diseases, hampering their usefulness as differential diagnostic markers \[[@CR8], [@CR9]\]. Indeed, it appears that current assay setups are not sensitive enough to detect, for example, disease-specific changes in tau processing. Together, these limitations have spurred the search for new tau modifications or epitopes that may improve early and differential diagnosis. Recently, a novel assay became available that can detect the non-phosphorylated tau fraction (p-tau~rel~) in CSF \[[@CR10]\]. This assay was developed to specifically detect tau protein with no phosphorylation at epitopes threonine T175, T181, and T231 (Fig. [1](#Fig1){ref-type="fig"}; \[[@CR10]\]). It was found that p-tau~rel~ is significantly higher in an AD/MCI cohort in comparison with controls, while differentiation between MCI and AD was not possible \[[@CR10]\]. The assay was also proposed to be helpful when differentiating between AD and other dementias, particularly tauopathies. The goal of this study was thus to investigate whether p-tau~rel~ can improve the diagnostic performance of the AD CSF biomarker panel for differential dementia diagnosis, comparing AD with a variety of non-AD dementias.Fig. 1Epitopes of different tau assays. Binding sites of antibodies making up total tau (*t-tau*), tau protein phosphorylated at threonine 181 (*p-tau* ~*181*~), and non-phosphorylated tau fraction *(p-tau* ~*rel*~ ) assays. Binding of antibody AT270 requires phosphorylation of threonine (T), while binding of antibody 1G2 requires threonine (T) to be not phosphorylated

Methods {#Sec2}
=======

Study cohort {#Sec3}
------------

The study population consisted of clinically diagnosed AD patients (*n* = 45), definite frontotemporal lobar degeneration (FTLD) patients (*n* = 45, of which 33 were FTLD-TDP, 10 FTLD-tau, and 2 FTLD-UPS), both clinical and definite Lewy body dementia (DLB) patients (*n* = 45, of which 19 definite), definite Creutzfeldt-Jakob disease (CJD) patients (*n* = 21), and cognitively healthy controls (*n* = 20). To ensure high diagnostic accuracy in the clinically diagnosed patients, only patients with clinical follow-up were included. All CSF samples were selected from the Institute Born-Bunge Biobank, Antwerp, Belgium \[[@CR1], [@CR11]\]. Patient and control-associated information included in the statistical analyses consisted of gender, age at CSF sampling, and age at death (if applicable). This study was approved by the ethics committee of UAntwerp, Antwerp, Belgium. Informed consent was obtained from all subjects.

Clinical diagnosis of AD was based on IWG-2 criteria and included the AD CSF biomarker panel (Aβ~1--42~ (cut-off: 638.5 pg/ml), t-tau (cut-off: 296.5 pg/ml), and p-tau~181~ (cut-off: 56.5 pg/ml)) \[[@CR2], [@CR11], [@CR12]\]. Definite FTLD diagnosis was defined by genetic carrier status (*n* = 30) and/or postmortem neuropathological confirmation of brain pathology (*n* = 28) \[[@CR13], [@CR14]\]. Clinical and neuropathological diagnoses of DLB were based on standard diagnostic criteria \[[@CR15]\]. All patients in the CJD subgroup met the clinical diagnostic criteria, including 14-3-3 positivity \[[@CR16]\], and were also RT-QuiC positive proving prion-pathology \[[@CR17]\]. Moreover, 10 CJD patients had neuropathological confirmation \[[@CR18]\]. The control group consisted of subjects with no history of neurological and psychiatric disorders or organic disease involving the central nervous system, as established by extensive clinical examination (patients with polyneuropathy: *n* = 8; patients with subjective physical complaints: *n* = 12).

Biomarker analysis {#Sec4}
------------------

Lumbar puncture, and CSF sampling and handling was performed according to a standard protocol \[[@CR11], [@CR19]\]. All samples were stored in polypropylene vials at --80°C until analysis.

CSF levels of Aβ~1--42~, t-tau, p-tau~181~, and p-tau~rel~ were determined with commercially available single-analyte enzyme-linked immunosorbent assay (ELISA) kits (one kit lot each), strictly following the manufacturer's instructions (INNOTEST β-Amyloid(~1--42~), INNOTEST hTau-Ag, and INNOTEST Phospho-Tau(~181P~) from Fujirebio Europe, Belgium; pTAU rel ELISA Kit from AJ Roboscreen, IBL International GmbH, Germany). All samples were run in duplicate and blinded for diagnosis. Intra-assay coefficient of variation (CV) was below 10% and inter-assay CV below 15% for all analytes.

Statistical analysis {#Sec5}
--------------------

Statistical testing was performed using IBM SPSS Statistics 23, GraphPad Prism 6, and MedCalc. Kruskall-Wallis analyses with post-hoc Dunn's multiple comparisons tests were performed to describe our patient cohort and compare biomarker levels between groups. Pairwise comparisons were only performed between controls and different dementia groups and between AD and different non-AD dementia groups. Categorical variables were analyzed with a Chi-square test. Spearman's rho was calculated to determine correlations. Receiver operating characteristic (ROC) curve analyses were used to obtain area under the curve (AUC) values for differentiation between groups. AUC values were compared using DeLong tests. Maximal sum of sensitivity and specificity (maximized Youden's index) was calculated to determine cut-off values. For all analyses, *p* values below 0.05 were considered statistically significant.

Results {#Sec6}
=======

Demographic, clinical, and biomarker data of all groups are summarized in Table [1](#Tab1){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}. Patient cohorts were not matched for age and gender but there was no observable effect of these parameters on biomarker levels (data not shown). Two FTLD patients and two CJD patients were excluded from statistical analysis as all their biomarker values were below the respective limits of detection, probably related to preanalytical factors. Concentration of t-tau was above the detection limit in 5/45 AD and 17/19 CJD cases and below the detection limit in 1/43 FTLD cases; Aβ~1--42~ was below the detection limit in 1/19 CJD cases only; p-tau~181~ was below the detection limit in 3/43 FTLD cases and 1/19 CJD cases; p-tau~rel~ was below the detection limit in 13/20 controls, 4/45 AD, 21/43 FTLD, and 13/45 DLB cases. As dilution of samples is not recommended for the three INNOTEST assays, out-of-range biomarker values were set to the lowest/highest detection point ±20%, and this value was used in statistical analyses. Due to the high number of samples with out-of-range biomarker values (especially the case for p-tau~rel~, see [Discussion](#Sec7){ref-type="sec"}), non-parametric statistical analyses were performed.Table 1Demographic, clinical, and biomarker dataControlsADFTLDDLBCJD*p* valueGender (% male/female) (*n*)55/45 (20)49/51 (45)51/49 (45)71/39 (45)33/67 (21)**0.049**Age at CSF sampling (years)69.4 (61.5--74.7)71.2 (66.7--79.2)63.6 (55.1--71.7)75.5 (71.2--81.2)67.2 (57.4--76.4)**\<0.001** ^**e**^MMSE (0--30) (*n*)NA\*20 (15--25) (42)21 (15--25) (29)19 (16--23) (38)NA0.54Aβ~1--42~ (pg/mL)812 (646--1108)509 (372--594)641 (457--858)547 (423--744)545 (300--686)**\<0.001** ^**a,c,d,e**^t-tau (pg/mL)257 (173--381)627 (429--928)320 (219--420)272 (232--398)\>1440^\$^**\<0.001** ^**a,d,e,f**^p-tau~181~ (pg/mL)40.3 (32.9--58.6)80.0 (60.5--105.0)36.7 (28.3--49.0)45.0 (39.8--64.7)46.0 (32.2--53.4)**\<0.001** ^**a,e,f,g**^p-tau~rel~ (pg/mL)32.0 (32.0--49.7)82.7 (46.6--135.7)32.0 (32.0--59.0)44.3 (32.0--73.8)1375 (738--1820)**\<0.001** ^**a,d,e,f,g**^Aβ~1--42~/t-tau3.40 (2.20--4.76)0.75 (0.50--1.02)2.00 (1.36--3.33)2.08 (1.10--3.13)0.39 (0.24--0.60)**\<0.001** ^**a,d,e,f**^Aβ~1--42~/p-tau~181~20.2 (14.7--24.7)5.8 (4.1--7.1)18.5 (11.1--25.0)13.7 (6.8--18.3)12.3 (6.8--19.6)**\<0.001** ^**a,c,e,f,g**^Aβ~1--42~/p-tau~rel~23.1 (16.2--30.3)5.0 (3.5--10.3)15.8 (9.2--21.6)11.6 (8.0--16.0)0.4 (0.2--0.9)**\<0.001** ^**a,c,d,e,f,g**^p-tau~181~/t-tau0.176 (0.156--0.197)0.132 (0.104--0.149)0.117 (0.097--0.149)0.158 (0.143--0.177)0.033 (0.024--0.038)**\<0.001** ^**a,b,d,f,g**^p-tau~181~/p-tau~rel~1.17 (0.85--1.30)1.00 (0.64--1.43)0.82 (0.61--1.11)0.94 (0.70--1.16)0.03 (0.03--0.06)**\<0.001** ^**d,g**^*APOE*ε4 carriers (%) (*n*)40.0 (5)61.1 (36)32.1 (28)33.3 (33)NA0.059Values are presented as median (interquartile range), percentage (%) or number (*n*)Gender distribution was compared by Chi-square testSignificant differences in clinical data and biomarker levels were determined by Kruskal-Wallis with post-hoc Dunn's correction: ^a^ controls vs. AD; ^b^ controls vs. FTLD; ^c^ controls vs. DLB; ^d^ controls vs. CJD; ^e^ AD vs. FTLD; ^f^ AD vs. DLB; ^g^ AD vs. CJDAge at CSF sampling was also significantly different for FTLD vs. DLB and CJD vs. DLBStatistically significant *p* values (\<0.05) are marked in bold\*MMSE only performed when clinically relevant (*n* = 3), no score \<27^\$^Most CJD patients had t-tau values above the detection limit, which were set to highest point of the standard curve +20%*Aβ* ~*1--42*~ amyloid-beta of 42 amino acids, *AD* Alzheimer's disease, *CJD* Creutzfeldt-Jakob disease, *CSF* cerebrospinal fluid, *DLB* dementia with Lewy bodies, *FTLD* frontotemporal lobar degeneration, *MMSE* Mini-Mental State Examination, *NA* not available, *p-tau* ~*181*~ tau protein phosphorylated at threonine 181, *p-tau* ~*rel*~ non-phosphorylated tau fraction, *t-tau* total tau protein Fig. 2Dot plots of individual markers and ratios. Dot plots showing individual biomarker levels in each subgroup. **a** amyloid-beta of 42 amino acids (*Aβ* ~*1--42*~); **b** total tau protein (*t-tau*); **c** tau protein phosphorylated at threonine 181(*p-tau* ~*181*~); **d** non-phosphorylated tau fraction (*p-tau* ~*rel*~); **e** Aβ~1--42~/t-tau; **f** Aβ~1--42~/p-tau~181~; **g** Aβ~1--42~/p-tau~rel~; **h** p-tau~181~/t-tau; **i** p-tau~181~/p-tau~rel~. Lines indicate median with interquartile range. *AD* Alzheimer's disease, *CJD* Creutzfeldt-Jakob disease, *DLB* dementia with Lewy bodies, *FTLD* frontotemporal lobar degeneration

AD patients had lower levels of Aβ~1--42~ (median (range), 509 (372--594) pg/mL) and higher t-tau (627 (429--928) pg/mL), p-tau~181~ (80.0 (60.5--105.0) pg/mL), and p-tau~rel~ (82.7 (46.6--135.7) pg/mL) levels than controls and non-AD patients, with the exception of CJD patients who had the highest t-tau and p-tau~rel~ levels (Table [1](#Tab1){ref-type="table"}). In all groups, the three different markers for tau significantly correlated with each other, with the correlation between t-tau and p-tau~rel~ being markedly stronger (Spearman's rho between 0.70--0.84) than the correlation between p-tau~181~ and p-tau~rel~ in every subgroup (Spearman's rho between 0.47--0.77; Additional file [1](#MOESM1){ref-type="media"}). Correlations with t-tau could not be calculated for CJD, given that 17/19 samples had a fixed t-tau value (i.e., the real value was above the detection limit of the assay).

To evaluate the diagnostic performance of p-tau~rel~ in comparison to the AD CSF biomarker panel, the single established AD marker with the highest AUC value was compared with that of p-tau~rel~. For example, the single marker which had the most diagnostic power to differentiate between AD and non-AD dementias was p-tau~181~, achieving an AUC of 0.883 (sensitivity: 88.9%; specificity: 76.4%). On the other hand, the AUC of p-tau~rel~ was significantly lower at 0.619 (sensitivity: 80.0%; specificity: 48.6%). Next to single markers, the AD biomarker ratio with the highest AUC value was also compared with its equivalent using p-tau~rel~. Continuing the example of AD versus non-AD differentiation, the best ratio with an AUC of 0.860 (sensitivity: 84.4%; specificity: 78.3%) was Aβ~1--42~/p-tau~181~. This value was thus compared to that of the Aβ~1--42~/p-tau~rel~ ratio, which was also significantly lower at 0.657 (sensitivity: 68.9%: specificity: 67.0%). Pairwise comparison between ROC curves with the highest AUC values, for both single markers and biomarker ratios, was performed for each AD versus non-AD dementia group (FTLD, DLB, and CJD), as well as for each different dementia group versus controls (Table [2](#Tab2){ref-type="table"}). A complete overview of all ROC curve analyses can be found in Additional file [1](#MOESM1){ref-type="media"}.Table 2Diagnostic performance of the AD CSF biomarker panel compared to p-tau~rel~AD panelp-tau~rel~Aβ~1--42~/p-tau~rel~p-tau~181~/p-tau~rel~AD vs. non-ADp-tau~181~0.8830.619^**\$**^Aβ~1--42~/p-tau~181~0.8600.657^**\$**^AD vs. FTLDp-tau~181~0.9330.799^**\$**^Aβ~1--42~/p-tau~181~0.9200.846^**\$**^AD vs. DLBt-tau0.8630.706^**\$**^Aβ~1--42~/t-tau0.8550.747^**\$**^AD vs. CJDt-tau0.8960.978**\***p-tau~181~/t-tau1.0001.000AD vs. controlst-tau0.9260.865Aβ~1--42~/t-tau0.9760.949FTLD vs. controlsAβ~1--42~0.6790.588p-tau~181~/t-tau0.8270.695DLB vs. controlsAβ~1--42~0.7470.717Aβ~1--42~/p-tau~181~0.7390.815CJD vs. controlst-tau0.9781.000Aβ~1--42~/t-tau1.0001.000The third column contains AUC values for the established single markers and biomarker ratios with the highest diagnostic valueAdjacent columns show AUC values of p-tau~rel~ and the equivalent ratio using p-tau~rel~Significant differences between AUC values (DeLong tests, *p* \< 0.05) are marked by an asterisk (**\***) when diagnostic power is significantly higher with addition of p-tau~rel~, and by a dollar sign (^**\$**^) when diagnostic power is significantly lower with addition of p-tau~rel~*Aβ* ~*1--42*~ amyloid-beta of 42 amino acids, *AD* Alzheimer's disease, *CJD* Creutzfeldt-Jakob disease, *CSF* cerebrospinal fluid, *DLB* dementia with Lewy bodies, *FTLD* frontotemporal lobar degeneration, *p-tau* ~*181*~ tau protein phosphorylated at threonine 181, *p-tau* ~*rel*~ non-phosphorylated tau fraction, *t-tau* total tau protein

Discussion {#Sec7}
==========

This study aimed to evaluate the diagnostic value of the non-phosphorylated tau fraction in comparison to that of the established AD biomarker panel for the differentiation between AD and non-AD dementias.

AD versus non-AD dementias {#Sec8}
--------------------------

When looking at the established AD biomarker panel, the differentiation between AD and non-AD dementias remained suboptimal, and our results confirm previous research in autopsy-confirmed patients that reported p-tau~181~ to be the most fundamental component of the AD CSF biomarker panel, showing the highest differential discriminatory power \[[@CR8]\]. Given that p-tau~rel~ is thought to inversely represent hyperphosphorylated tau \[[@CR10]\], a comparable performance to p-tau~181~ could be expected. However, our results showed that the use of p-tau~rel~ as a single marker resulted in a significantly lower AUC value for the comparison between AD and non-AD, and also the combination of p-tau~rel~ together with the three established AD biomarkers did not improve the differential diagnostic accuracy for these dementia groups.

As tau-positive inclusions can also be found as a distinct primary pathology in a significant subgroup of FTLD \[[@CR20]\], and pathological hyperphosphorylation of tau might be different to that in AD, there was a diagnostic potential for p-tau~rel~ to be of value in the differentiation between AD and FTLD. This was, however, not the case, as both the AUC value of p-tau~rel~ alone and that of the Aβ~1--42~/p-tau~rel~ ratio were significantly lower than those of the equivalent established AD biomarkers. It should be noted that the difference in AUC values for the biomarker ratio lost significance when *APOE*ε4 carrier status was taken into account, as this had an effect on Aβ~1--42~ values in FTLD patients (*p* = 0.036). Finally, there was no significant difference for any single biomarker or biomarker ratio between FTLD-tau-positive and FTLD-tau-negative subgroups (data not shown).

Patients with DLB can often present with an AD-like co-pathology, thus limiting the value of the established AD biomarkers \[[@CR21]\]. Nonetheless, reasonable AUC values were obtained when comparing AD and DLB, corroborating our patient selection of DLB with almost half having a neuropathological confirmation. While there is no direct reason to assume different results by using p-tau~rel~, there was a significant decrease in AUC values for both single marker and biomarker ratio ROC analyses.

One interesting result was found for p-tau~rel~ as a single marker in the comparison of AD and CJD, obtaining a significantly higher AUC value than that of t-tau. CJD is typically characterized by very high concentrations of t-tau, reflecting the extensive neurodegeneration, and the protein can act as surrogate marker for the disease \[[@CR22], [@CR23]\]. On the other hand, the p-tau~181~/p-tau~rel~ ratio did not perform better than the p-tau~181~/t-tau ratio. This suggests that the (relatively) low AUC value for t-tau in the AD vs. CJD differentiation is most likely due to the limited detection range of the used t-tau assay, as true t-tau values could not be obtained for 17/19 CJD cases. As such, p-tau~rel~ is not necessarily a better biomarker in CJD, but the assay gives more accurate results in this cohort.

AD and non-AD dementias versus controls {#Sec9}
---------------------------------------

Within the established AD biomarker panel, an excellent AUC value was found for the ROC curve between AD and controls, confirming the sensitivity of these biomarkers for AD detection. The AUC values obtained with the addition of p-tau~rel~ were not significantly different for either single marker or biomarker ratio. However, the observed AUC value for p-tau~rel~ when differentiating AD from controls (0.865; sensitivity: 88.9%; specificity: 75.0%) was lower than that obtained by Lewczuk et al. (0.976; sensitivity: 94.8%; specificity: 97.6%) \[[@CR10]\]. The decreased specificity in this study can be explained by the fact that many control subjects had p-tau~rel~ concentrations below the detection limit (see below). While this issue should be acknowledged when interpreting all ROC analyses including controls, we believe that there is no major effect on the results. In fact, as the real p-tau~rel~ values of controls are even lower than what we report, differences between groups would become larger.

Since Aβ~1--42~ and tau are related to AD pathology, it was expected that differentiation between non-AD dementias and controls would be less successful. Indeed, similar to the comparison between AD and FTLD, the tau-pathology seen in a subset of FTLD cases did not result in significant differences in either t-tau, p-tau~181~, or p-tau~rel~ levels between FTLD and controls. Overall, single markers and biomarker ratios achieved poor AUC values in this comparison, with the exception of the p-tau~181~/t-tau ratio (because the small differences in these markers were in opposite directions). Also for the differentiation between DLB and controls AUC values were poor, and no significant change was observed when p-tau~rel~ was added, although the Aβ~1--42~/p-tau~rel~ ratio had the highest raw AUC value. One successful differentiation was the diagnosis of CJD, with high AUC values for both t-tau and p-tau~rel~ alone as well as any ratio including t-tau or p-tau~rel~. This can again be explained by the fact that (non-phosphorylated) tau reflects the extensive neurodegeneration in CJD in the absence of tau-pathology \[[@CR23]\].

Study limitations: p-tau~rel~ biomarker values {#Sec10}
----------------------------------------------

This study was subject to at least two limitations. Firstly, the number of patients in each dementia group was quite small as we chose to select only patients with high diagnostic certainty (by either pathological confirmation or clinical follow-up). While this allowed for a clear separation between groups, it also put a limit on statistical analyses. Secondly, there was a high number of samples with p-tau~rel~ levels below the detection limit. This was especially the case in cohorts which typically also have relatively low t-tau values (controls, FTLD, DLB). As our results show p-tau~rel~ concentrations to be at least one sixth of t-tau levels (not seen in CJD because of the upper limit of detection in the t-tau assay) very low p-tau~rel~ values are not unexpected. It thus appears the assay used lacks the necessary sensitivity to detect true levels of p-tau~rel~, therefore precluding its potential use as biomarker in differential dementia diagnosis. Then again, the study by Lewczuk et al. found p-tau~rel~ concentrations from controls to fall within the detection range of the assay \[[@CR10]\]. Going into detail, limited raw data in Lewczuk et al. \[[@CR10]\] showed an average value of 109 ± 32.0 pg/mL p-tau~rel~ in AD/MCI and 62.1 ± 9.3 pg/mL in controls. In our study, the value for AD patients is very comparable (mean of 108 ± 13 pg/mL), while our control group had strikingly lower values with many p-tau~rel~ levels below the detection limit (mean of 39.4 ± 3.0 pg/mL). This difference is possibly related to control subject selection, but as there is only one other study to compare our results to, future independent research using the p-tau~rel~ assay will be necessary to interpret these discrepancies and to validate our results.

Conclusions {#Sec11}
===========

In conclusion, this study shows that the addition of p-tau~rel~ to the AD CSF biomarker panel did not improve the differential diagnosis between AD and non-AD dementias. However, limited sensitivity of the assay might mask the potential diagnostic value of non-phosphorylated tau as a biomarker.

Additional file {#Sec12}
===============

Additional file 1: Table S1.Correlations between different markers for tau. **Table S2.** Diagnostic performance of CSF biomarkers for differentiation between dementias and controls or differentiation between AD and non-AD dementias. (DOCX 28 kb)
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:   Alzheimer's disease

AUC

:   Area under the curve

Aβ~1--42~

:   Amyloid-beta of 42 amino acids

CJD

:   Creutzfeldt-Jakob disease

CSF

:   Cerebrospinal fluid

CV

:   Coefficient of variation

DLB

:   Dementia with Lewy bodies

ELISA

:   Enzyme-linked immunosorbent assay

FTLD

:   Frontotemporal lobar degeneration

MCI

:   Mild cognitive impairment

MMSE

:   Mini-mental state examination

p-tau

:   Phosphorylated tau protein

p-tau~181~

:   Tau protein phosphorylated at threonine 181
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:   Non-phosphorylated tau fraction
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:   Receiver operating characteristic

t-tau

:   Total tau protein
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